Navigation Links
GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
Date:9/8/2009

NEW YORK, NY, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Anders Boegh Jensen to its Scientific Advisory Board (SAB).

Dr. Boegh Jensen will contribute his considerable expertise in biotechnology and molecular biology to GENova's business of identifying, evaluating and developing pioneering research drugs. His expertise is acknowledged by companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec.

Aaron Whiteman, CEO of GENova, says, "We are delighted to have Mr. Boegh Jensen join the SAB. His credentials and experience in the biotech field will be an asset to GENova as we continue to identify promising cancer-fighting drug patents."

Anders Boegh Jensen, Ph.D.

Anders Boegh Jensen is a biochemist who specializes in biotechnology, genetics and molecular biology. He is currently the Director at Poalis, a plant-based biotechnology company, and serves as an Industrial Representative Board Member at the Danish Society for Biochemistry and Molecular Biology. Dr. Boegh Jensen is also frequently published in leading industry journals such as "Cell". His previous position was Associate Professor at the Institute of Molecular Biology at the University of Copenhagen where he helped modernize biology education and developed advanced Ph.D. courses.

Anders Boegh Jensen's academic credentials include: completion of a Master's thesis at the Institute of Molecular Biology, University of Copenhagen in 1989; a one-year research term at the Carlsberg Research Laboratory; and being awarded a four-year European Union BRIDGE mobility fellowship for his post-graduate research training at the Dept. of Plant Molecular Genetics, CID, CSIC, Barcelona, Spain. He completed his Ph.D thesis in Molecular Biology and Genetics in 1994.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genova files patent for new prostate cancer treatment
2. GENova names Dr. John Savin as Vice President
3. GENova names Aaron Whiteman as CEO
4. Allscripts to Announce Fiscal First Quarter Results on September 29, 2009; Company Appoints Vice President of Investor Relations
5. KV Pharmaceutical Appoints Interim Chief Financial Officer
6. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
7. Mindray DS USA Appoints Michael Thompson Vice President of U.S. Ultrasound Sales
8. XLHealth Appoints New Controller to Lead Financial Compliance, Accounting Initiatives
9. IMIA Interpreter Association Appoints Brazil Representative
10. HCA Appoints Dr. Richard Tayrien Chief Health Information Officer
11. SCOLR Pharma, Inc. Appoints Stephen J. Turner as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 26, 2016 , ... On May 23rd during the National Eye Institute’s “Healthy ... water advocate, was honored by Ashram, Inc. as the world’s foremost water visionary. , ... the banks of the Nile to fill their red clay pots with life-sustaining water.” ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The introduction of ... ADDING PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce ... the football front we have Brian Quick, wide receiver for Los Angeles who was ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... . With over 20 years of experience in leading technology and human resources ... years of university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio ...
(Date:5/26/2016)... ... , ... May 2016 – Lips may be a central feature on our ... numbers of clients now ask about lip plumping and primping techniques and want tips ... Advanced Dermatology P.C. , The trend is a national one, with 2.4 ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is happy to announce the launch of its brand equity product, Brandvantage. ... to reflect the dynamic landscape of modern consumer decision-making. The proprietary framework ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... role, Marziani will lead the company,s business development and sales team, exploring new opportunities ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
Breaking Medicine Technology: